SquamousCellCarcinomaofSkin near Yonkers, NY

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Joseph Jurcic is a Professor of Medicine at Columbia University Medical Center and the Director of the Hematologic Malignancies Section within the Division of Hematology/Oncology. He specializes in Medical Oncology and focuses on leukemia, myelodysplastic syndromes, and myeloproliferative disorders. Based in New York, NY, Dr. Jurcic is affiliated with NewYork-Presbyterian/Columbia University Irving Medical Center. He received his M.D. from the Perelman School of Medicine at the University of Pennsylvania and completed his training at Barnes-Jewish Hospital and Memorial Sloan Kettering Cancer Center. He is board-certified in both Medical Oncology and Hematology.Dr. Jurcic's clinical expertise includes the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndromes. His research interests encompass acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy, developing novel small molecule inhibitors, and molecular monitoring of minimal residual disease. Recognized as one of New York Magazine's "Best Doctors" from 2014 to 2024, he has authored or co-authored over 80 articles and book chapters. He has served as the principal investigator on more than 25 clinical trials. Additionally, Dr. Jurcic lectures at national and international conferences and is the Leukemia Section Editor for The Oncologist.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow. Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Biography: Dr. Payne is the Herbert and Florence Irving Professor and Chair of Dermatology at Columbia University Irving Medical Center. She received her BS degree in Biology from Stanford University and an MD/PhD degree in Molecular and Cellular Biology from Washington University School of Medicine, followed by dermatology residency and postdoctoral fellowship training at the University of Pennsylvania. Dr. Payne is the 2024-2025 President of the Society for Investigative Dermatology and is a member of the American Society for Clinical Investigation, NIH/NIAMS Advisory Council, and International Pemphigus and Pemphigoid Foundation Medical Advisory Council. She also serves as co-chair of the Scientific Advisory Board at Cabaletta Bio, a company she co-founded to enable the first precision cellular immunotherapies for autoimmunity to enter human clinical trials.

Biography: Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic. During fellowship, he conducted outcomes research with a focus on quality of life and treatment-related toxicities in plasma cell disorders. After fellowship, he started his job as Assistant Professor of Medicine at the Multiple Myeloma and Amyloidosis Program at Columbia University Irving Medical Center. Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.